Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular Prevention in the Cancer Survivor

  • Coronary Heart Disease (E Gianos and B Shah, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Cancer survivorship should be defined starting not from completion of treatment, but from the time of diagnosis. Assessing and controlling the cancer patient’s cardiovascular risk before, during, and after treatment is crucial to improving their overall outcome. There are many cancer therapies, including but not limited to anthracyclines, radiation, and vascular signaling pathway inhibitors which should be considered nontraditional cardiovascular risk factors with significant morbidity. Monitoring novel populations, such as a younger age group, for ischemic coronary disease or congestive heart failure (CHF) is not intuitive to many clinicians. Symptoms of CHF and coronary artery disease overlap with common side effects of cancer and cancer treatment. Cancer survivors may also have fewer typical symptoms of cardiovascular disease. Increased surveillance and aggressive control of cardiovascular disease is important in cancer patients both while undergoing active treatment and in the long term. Despite the increasing interest in cardio-oncology, data-driven guidelines are lacking due to small study sizes and low event rates over a short period of time. Most practice guidelines have been based on clinical practice and expert opinion. The list of cardiotoxic cancer therapies continues to grow each year. This review is not intended to be a comprehensive review of all cancer therapy toxicity, but will focus on recent literature regarding prevention of CHF and coronary artery disease (CAD) during active cancer therapy as well as current screening guidelines for long-term survivors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Edwards BK et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–314.

    Article  PubMed  Google Scholar 

  2. Survivorship Definitions. 8/18/14]; Available from: http://cancercontrol.cancer.gov/ocs/statistics/definitions.html.

  3. DeSantis CE et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.

    Article  PubMed  Google Scholar 

  4. Lloyd-Jones DM et al. Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry). Am J Cardiol. 2007;99(4):535–40.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Yancy CW et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):1495–539.

    Article  Google Scholar 

  6. Cardinale D et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20.

    Article  CAS  PubMed  Google Scholar 

  7. Thakur A, Witteles RM. Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J Card Fail. 2014;20(3):155–8.

    Article  PubMed  Google Scholar 

  8. Steinherz LJ et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266(12):1672–7.

    Article  CAS  PubMed  Google Scholar 

  9. American College of Cardiology Foundation Appropriate Use Criteria Task, F et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. J Am Coll Cardiol. 2011;57(9):1126–66.

    Article  Google Scholar 

  10. Vrooman LM et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL consortium. Eur J Cancer. 2011;47(9):1373–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Lipshultz SE et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Hensley ML et al. American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127–45.

    Article  CAS  PubMed  Google Scholar 

  13. Plana JC et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39. Clinical cardiologists and echocardiographers from 20 university hospitals throughout the world with experience in a cancer population review the available literature and propose guidelines and algorithms regarding the use of multimodality imaging in cancer patients. The utility of 3D echo, diastolic and tissue indices, global longitudinal strain, cardiac MRI are reviewed. Several clinical algorithms are proposed. A cardio-oncology specific echo protocol is also proposed.

    Article  PubMed  Google Scholar 

  14. Negishi K et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493–8.

    Article  PubMed  Google Scholar 

  15. Thavendiranathan P et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751–68. There have been many trials using strain imaging in the cancer population. Most of these trials are very small and underpowered. This meta-analysis pools data to help confirm the value of strain in early detection.

    Article  PubMed  Google Scholar 

  16. Cardinale D et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749–54.

    Article  CAS  PubMed  Google Scholar 

  17. Cardinale D et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474–81.

    Article  CAS  PubMed  Google Scholar 

  18. Morris PG et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011;17(10):3490–9.

    Article  CAS  PubMed  Google Scholar 

  19. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900–9. By pooling the many small trials using cardioprotective therapy for prevention of cardiotoxicity, the trends and gaps which need to be filled in are more clearly seen.

    Article  CAS  PubMed  Google Scholar 

  20. Negishi K et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014;15(3):324–31. This is one of the larger studies of 159 patients showing speckle strain data during anthracycline and/or trastuzumab therapy. This study also looked at treatment of abnormal GLS with beta-blocker therapy.

    Article  PubMed  Google Scholar 

  21. Lipshultz SE et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013;119(19):3555–62.

    PubMed Central  CAS  PubMed  Google Scholar 

  22. Blanco JG et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the children’s oncology group. J Clin Oncol. 2012;30(13):1415–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Wang X et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children’s oncology group. J Clin Oncol. 2014;32(7):647–53.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Visscher H et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422–8.

    Article  PubMed  Google Scholar 

  25. Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  CAS  PubMed  Google Scholar 

  26. Slamon D et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Perez EA et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Wang SY et al. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Res Treat. 2014;146(2):411–9.

    Article  PubMed  Google Scholar 

  29. Cardinale D et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–6.

    Article  CAS  PubMed  Google Scholar 

  30. Sawaya H et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Ky B et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809–16. Previous studies have suggested the utility of troponin levels to predict increased risk for LV dysfunction. This is the first study to suggest myeloperoxidase as a potential biomarker for LV dysfunction in anthracycline/trastuzumab therapy.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Chu TF et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Escudier B et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  PubMed  Google Scholar 

  34. Schmidinger M et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12.

    Article  PubMed  Google Scholar 

  35. Labs, P. Sutent. Medication Guide May 2011 9/22/14]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf.

  36. Rini BI et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103(9):763–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. George S et al. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012;23(12):3180–7.

    Article  CAS  PubMed  Google Scholar 

  38. Bilen MA et al. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014;32(4):717–22.

    Article  CAS  PubMed  Google Scholar 

  39. Di Lorenzo G et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20(9):1535–42.

    Article  PubMed  Google Scholar 

  40. Motzer RJ et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    Article  CAS  PubMed  Google Scholar 

  41. Subramaniam S, Zell JA, Kunz PL. Everolimus causing severe hypertriglyceridemia and acute pancreatitis. J Natl Compr Canc Netw. 2013;11(1):5–9.

    PubMed  Google Scholar 

  42. Porta C et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011;47(9):1287–98.

    Article  CAS  PubMed  Google Scholar 

  43. Paplomata E, Zelnak A, O’Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat. 2013;140(3):453–62.

    Article  CAS  PubMed  Google Scholar 

  44. Saigal CS et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–500.

    Article  CAS  PubMed  Google Scholar 

  45. Levine GN et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121(6):833–40.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Armstrong GT et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673–80.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Swerdlow AJ et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206–14.

    Article  PubMed  Google Scholar 

  48. Heidenreich PA et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol. 2007;25(1):43–9.

    Article  PubMed  Google Scholar 

  49. Ezaz G et al. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472. A clinical risk score is developed in a real world population which may help risk stratify older women to low or high heart failure risk with adjuvant trastuzumab therapy.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Demark-Wahnefried W et al. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005;23(24):5814–30.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Hudis CA, Jones L. Promoting exercise after a cancer diagnosis: easier said than done. Br J Cancer. 2014;110(4):829–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Moller T et al. At cancer diagnosis: a ‘window of opportunity’ for behavioural change towards physical activity. A randomised feasibility study in patients with colon and breast cancer. BMJ Open. 2013;3(11):e003556.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Kavanagh T et al. Prediction of long-term prognosis in 12 169 men referred for cardiac rehabilitation. Circulation. 2002;106(6):666–71.

    Article  PubMed  Google Scholar 

  54. Francis DP et al. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). Eur Heart J. 2000;21(2):154–61.

    Article  CAS  PubMed  Google Scholar 

  55. Jones LW et al. Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. Cancer. 2010;116(20):4825–32.

    Article  PubMed  Google Scholar 

  56. Hornsby WE et al. Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. Acta Oncol. 2014;53(1):65–74.

    Article  PubMed  Google Scholar 

  57. Jones LW et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012;30(20):2530–7.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Schmitz KH et al. American college of sports medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.

    Article  PubMed  Google Scholar 

  59. Oeffinger KC et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.

    Article  CAS  PubMed  Google Scholar 

  60. Mertens AC et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the childhood cancer survivor study. J Clin Oncol. 2001;19(13):3163–72.

    CAS  PubMed  Google Scholar 

  61. Kero AE, et al. Late mortality among 5-year survivors of early onset cancer: a population-based register study. Int J Cancer. 2014.

  62. Kero AE et al. Cardiovascular morbidity in long-term survivors of early-onset cancer: a population-based study. Int J Cancer. 2014;134(3):664–73.

    Article  CAS  PubMed  Google Scholar 

  63. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, version 4.0. October 2013 9/24/14]; Available from: http://www.survivorshipguidelines.org/pdf/LTFUGuidelines_40.pdf. * The most comprehensive and commonly used guideline for all late effects of cancer therapy in children, adolescents and young adults was just updated in 2013. This is an important reference for any clinician caring for pediatric cancer survivors.

  64. Hull MC et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831–7.

    Article  CAS  PubMed  Google Scholar 

  65. Yeh JM, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med. 2014;160(10):661–71.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Wong FL et al. Cost-effectiveness of the children’s oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med. 2014;160(10):672–83. This is a thorough overview of late cardiac effects in entire spectrum of cancer treatment in children and young adults.

    Article  PubMed  Google Scholar 

  67. van Leeuwen-Segarceanu EM et al. Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease. Cancer Treat Rev. 2011;37(5):391–403.

    Article  PubMed  Google Scholar 

  68. Lipshultz SE et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927–95.

    Article  PubMed  Google Scholar 

  69. Lipshultz SE et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20(23):4517–22.

    Article  CAS  PubMed  Google Scholar 

  70. Smith WA et al. Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude lifetime cohort study. Cancer. 2014;120(17):2742–50.

    Article  PubMed  Google Scholar 

  71. Bardia A et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2012;131(3):907–14.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Herceptin P (trastuzumab) package insert. 10/2010 9/24/14]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf.

  73. de Azambuja E et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01). J Clin Oncol. 2014;32(20):2159–65. This study is the longest cardiac follow-up to date for large adjuvant trastuzumab trial.

    Article  PubMed  Google Scholar 

  74. Romond EH et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Chen J et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–12. This SEER-Medicare cohort receiving adjuvant trastuzumab treatment showing higher CHF/CM rates than reported in the clinical trials population may more accurately reflect “real world” oncology practice.

    Article  CAS  PubMed  Google Scholar 

  76. Correa CR et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol. 2007;25(21):3031–7.

    Article  PubMed  Google Scholar 

  77. Darby SC et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.

    Article  CAS  PubMed  Google Scholar 

  78. Demirci S et al. Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int J Radiat Oncol Biol Phys. 2009;73(4):980–7.

    Article  PubMed  Google Scholar 

  79. Goody RB et al. Unintended cardiac irradiation during left-sided breast cancer radiotherapy. Br J Radiol. 2013;86(1022):20120434.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Steingart RM et al. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. Semin Oncol. 2013;40(6):690–708.

    Article  PubMed  Google Scholar 

  81. van den Belt-Dusebout AW et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006;24(3):467–75.

    Article  PubMed  Google Scholar 

  82. Meinardi MT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18(8):1725–32.

    CAS  PubMed  Google Scholar 

  83. Haugnes HS et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012;30(30):3752–63.

    Article  PubMed  Google Scholar 

  84. Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw. 2012;10(4):537–44.

    CAS  PubMed  Google Scholar 

  85. de Haas EC et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol. 2013;24(3):749–55.

    Article  PubMed  Google Scholar 

  86. Willemse PM et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer. 2013;109(1):60–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Carol L. Chen declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 260, New York, NY, 10065, USA

    Carol L. Chen

Authors
  1. Carol L. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol L. Chen.

Additional information

This article is part of the Topical Collection on Coronary Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, C.L. Cardiovascular Prevention in the Cancer Survivor. Curr Atheroscler Rep 17, 6 (2015). https://doi.org/10.1007/s11883-014-0484-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-014-0484-3

Keywords

Search

Navigation